Zinacef — Competitive Intelligence Brief

Zinacef (CEFUROXIME) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cephalosporin Antibacterial. Area: Cardiovascular.

marketed Cephalosporin Antibacterial Carbonic anhydrase 2 Cardiovascular Small molecule

Target snapshot

Zinacef (CEFUROXIME) — GSK. Zinacef works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Zinacef TARGET	CEFUROXIME	GSK	marketed	Cephalosporin Antibacterial	Carbonic anhydrase 2	1983-01-01
Tri-Luma	HYDROQUINONE	Galderma Labs Lp	marketed	Melanin Synthesis Inhibitor [EPC]	Carbonic anhydrase 2	2002-01-01
Trusopt	DORZOLAMIDE	Merck & Co.	marketed	Carbonic Anhydrase Inhibitor	Carbonic anhydrase 2	1994-01-01
Ammonul	SODIUM BENZOATE		marketed	sodium benzoate	Carbonic anhydrase 2	1987-01-01
Lithostat	ACETOHYDROXAMIC ACID	Mission Pharma	marketed	Urease Inhibitor [EPC]	Carbonic anhydrase 2	1983-01-01
Cinobac	CINOXACIN	Eli Lilly	marketed	cinoxacin	Carbonic anhydrase 2	1980-01-01
Dihydrex	BENZTHIAZIDE	Ah Robins Inc	marketed	benzthiazide	Calcium-activated potassium channel subunit alpha-1, Carbonic anhydrase 1, Carbonic anhydrase 2	1960-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cephalosporin Antibacterial class)

1. · 5 drugs in this class
2. GSK · 3 drugs in this class
3. Shionogi · 2 drugs in this class
4. Burke Therap · 1 drug in this class
5. Cubist Pharms · 1 drug in this class
6. Sterimax · 1 drug in this class
7. Vansen Pharma · 1 drug in this class
8. AbbVie · 1 drug in this class
9. Baxter · 1 drug in this class